TherapeuticsMD, Inc.
TXMD
Rank in Stocks
#26563
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to... TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17Γ-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Share Price
$1.69
Last synced: 2026-11-09
Market Cap
$19.56M
Change (1 day)
-2.87%
Change (1 year)
3.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TherapeuticsMD, Inc. (TXMD)
Category
Healthcare
EPS for TherapeuticsMD, Inc. (TXMD)
EPS as of June 2026 TTM: $-0.02
According to TherapeuticsMD, Inc.'s latest financial reports, its current EPS (TTM) is $-0.02. At the end of 2025 the company had an EPS of $-0.05, an increase over its 2024 EPS of $-0.19.
EPS history for TherapeuticsMD, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.02 | -62.40% |
| 2025 | $-0.05 | -74.11% |
| 2024 | $-0.19 | -65.45% |
| 2023 | $-0.55 | -104.43% |
| 2022 | $12.41 | -148.04% |
| 2021 | $-25.83 | -33.05% |
| 2020 | $-38.58 | -3.04% |
| 2019 | $-39.79 | 35.02% |
| 2018 | $-29.47 | 57.51% |
| 2017 | $-18.71 | -18.37% |
| 2016 | $-22.92 | -6.68% |
| 2015 | $-24.56 | 35.62% |
| 2014 | $-18.11 | 62.57% |
| 2013 | $-11.14 | -41.86% |
| 2012 | $-19.16 | 85.48% |
| 2011 | $-10.33 | -88.63% |
| 2010 | $-90.82 | -92.03% |
| 2009 | $-1.14K | 75.73% |
| 2008 | $-648.45 | -217.87% |
| 2007 | $550.14 | 219,956.00% |
| 2006 | $0.25 | -100.30% |
| 2005 | $-83.33 | -61.54% |
| 2004 | $-216.67 | -1,386.64% |
| 2003 | $16.84 | -77.24% |
| 2002 | $74.00 | -26.08% |
| 2001 | $100.11 | 372.89% |
| 2000 | $21.17 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -34,681.91% |
DE
|
|
| $6.08 | -32,427.66% |
DE
|
|
| $1.55 | -8,347.87% |
JP
|
|
| $3.66 | -19,568.09% |
CH
|
|
| $0.45 | -2,493.62% |
IL
|
Questions about TherapeuticsMD, Inc.'s earnings per share (EPS)
What is TherapeuticsMD, Inc.'s earnings per share (EPS)?
TherapeuticsMD, Inc.'s earnings per share (EPS) over the last twelve months is $-0.02, as of Jun 2026.
What was TherapeuticsMD, Inc.'s earnings per share (EPS) in 2025?
In 2025, TherapeuticsMD, Inc.'s earnings per share (EPS) was $-0.05, compared with $-0.19 in 2024.
How has TherapeuticsMD, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, TherapeuticsMD, Inc.'s earnings per share (EPS) was highest in 2022 ($12.41) and lowest in 2020 ($-38.58).
How does TherapeuticsMD, Inc.'s earnings per share (EPS) compare with similar companies?
TherapeuticsMD, Inc.'s earnings per share (EPS) ($-0.02) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.